

## 2022 340B Covered Entity Purchases

Entity Type	2022 Total Purchases
Disproportionate Share Hospitals	\$41,818,751,617
Health Center Programs	\$2,766,861,692
Children's Hospitals	\$1,662,587,169
Rural Referral Centers	\$1,327,392,962
Ryan White HIV/AIDS Program Part A	\$1,428,740,890
Sexually Transmitted Disease Clinics	\$1,200,458,142
Critical Access Hospitals	\$743,195,969
Ryan White HIV/AIDS Program Part C	\$628,990,476
Sole Community Hospitals	\$516,652,406
Free-standing Cancer Centers	\$420,119,631
Ryan White HIV/AIDS Program Part B	\$262,542,199
Ryan White Part B AIDS Drug Assistance Program (ADAP) Direct Purchase Option	\$217,504,434
Comprehensive Hemophilia Treatment Centers, 789,584	\$317,598,376
Federally Qualified Health Center Look-Alike Program	\$248,789,584
Family Planning Clinics	\$62,042,508
Ryan White HIV/AIDS Program Part D	\$45,199,596
Tribal Contract/Compact with IHS (P.L. 93-638)	\$39,283,424
Tuberculosis Clinics	\$7,097,302
Urban Indian Hospitals	\$1,671,618
Black Lung Clinics	\$279,357
Ryan White Part B ADAP Rebate Option	\$31,500
Native Hawaiian Health Care Programs	27,912
<b>Total</b>	<b>\$53,715,818,765</b>

**Source:** 340B Prime Vendor Program, August 12, 2023

**Note:** These purchase data are provided by the 340B Prime Vendor Program and do not capture the entire universe of 340B Program purchases (e.g. the Prime Vendor Program does not collect all direct purchases). The Prime Vendor Program was established pursuant to section 340B(a)(8) of the Public Health Service Act for price negotiation, distribution facilitation, and other activities in support of the 340B Drug Pricing Program. It is managed by Apexus through a contract with the Health Resources and Services Administration. These figures are accurate as of Aug. 12, 2023. The purchase data provided is a culmination of transactional data captured by the Prime Vendor Program at a given point in time. The totals reflected in this chart may change, as the 340B Prime Vendor Program is constantly reviewing and updating the data as transactions occur, and there are times when adjustments to invoices are made, which impact the total purchases reported. HRSA estimates that **at least** \$470 million of the total amount were purchases above the 340B ceiling price due to manufacturers restricting a covered entity's ability to obtain the 340B discount **when the entity dispensed the drug through a pharmacy under contract with the entity**. Entity organizations are defined at section 340B(a)(4) of the Public Health Service Act.